Nanomedicine: Nanotechnology, Biology and Medicine Welcomes New Editor-in-Chief
Editor-in-Chief Lajos P. Balogh, PhD to lead online journal
Philadelphia, 5 March 2009 – Elsevier is honored to announce today that Lajos P. Balogh, PhD, has been named the new Editor-in-Chief of Nanomedicine: Nanotechnology, Biology and Medicine, an online journal published by Elsevier.
Dr. Balogh has been involved in nanotechnology research since 1996 and is presently active in various interdisciplinary directions. His major research interest is the construction of well-defined organic/inorganic hybrid medical nanodevices for targeted detection, imaging, and biophysical therapy of cancer based on dendrimers, smart contrast agents, and radioactive nanocomposites. He has published over 180 scientific papers and has been awarded 12 patents on dendrimers, nanocomposites, cancer imaging and treatment, analytical chemistry, separation science, technology, polymer synthesis and characterization.
Dr. Balogh is currently a Professor of Biomedical Nanotechnology and Director of Nanotechnology Research in the Department of Radiation Medicine at the Roswell Park Cancer Institute, Buffalo, NY. He is also the Co-Director of the NanoBiotechnology Center at Roswell and Professor of Oncology at the University at Buffalo, SUNY.
Kate Williamson, Elsevier Associate Publisher for Nanomedicine: Nanotechnology, Biology and Medicine, commented: “We are so pleased to welcome Dr. Balogh as Editor-in-Chief of Nanomedicine: NBM. Dr. Balogh's expertise in the field will be a tremendous asset to the journal. We look forward to working with Dr. Balogh and the editorial team to carry out his vision for the journal.”
# # #
About Nanomedicine: Nanotechnology, Biology and Medicine
Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is an international, peer-reviewed journal. Each quarterly issue of Nanomedicine: NBM presents basic, clinical, and engineering research in the field of nanomedicine. Article categories include basic, diagnostic, experimental, clinical, engineering, pharmacologic, and toxicologic nanomedicine. The Journal is indexed in MEDLINE from Volume 1, issue 1 and is available online at www.nanomedjournal.com.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby’s Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.
Media Contact:
Caroline Foote
Elsevier
+1 215 239 3652
c.foote@elsevier.com
